VERAXA Biotech AG (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, which aims to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells, achieving dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
The findings further validate the potential of the BiTAC-ADC platform and complement VERAXA's BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. According to the company, these platforms represent a significant step forward in addressing the challenge of off-target toxicity in cancer therapies, which often limits the efficacy of traditional approaches.
VERAXA management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. This event could provide a key avenue for the company to attract collaborators and advance its pipeline. The implications of this announcement are substantial for the oncology field, as the BiTAC-ADC platform offers a novel mechanism to deliver potent therapies directly to tumor cells while sparing healthy tissue. If successful in clinical trials, this approach could improve patient outcomes and reduce side effects for various solid tumors.
For the industry, VERAXA's technology represents a potential new class of antibody-based therapeutics. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a renowned institution known for pioneering life science research. The BiTAC-ADC platform is part of a broader suite of transformative technologies being developed by VERAXA, which includes bispecific T cell engagers and bispecific ADCs.
The proof-of-concept data is a critical milestone, providing early evidence that the platform can work as designed. Investors and researchers will be watching closely for further developments, especially as the company moves toward clinical trials. The full press release is available at https://ibn.fm/QiPhH. More information about VERAXA and its latest news can be found in the company's newsroom at http://ibn.fm/VRXA.
